Nicklas J Johansen
Overview
Explore the profile of Nicklas J Johansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nielsen C, Ohrstrom C, Houji I, Helsted M, Krogh L, Johansen N, et al.
Diabetes Care
. 2023 Oct;
46(12):2208-2217.
PMID: 37819999
Objective: Postbariatric hypoglycemia affects >50% of individuals who have undergone Roux-en-Y gastric bypass surgery. Despite the often debilitating nature of this complication, existing treatment options are limited and often inefficient....
2.
Johansen N, Dejgaard T, Lund A, Schluntz C, Hartmann B, Holst J, et al.
Diabetes Obes Metab
. 2021 Oct;
24(2):221-227.
PMID: 34617375
Aim: To evaluate the efficacy of the short-acting glucagon-like peptide-1 receptor agonist, exenatide, added to insulin therapy in type 1 diabetes on bone mineral density and bone turnover markers. Materials...
3.
Johansen N, Dejgaard T, Lund A, Schluntz C, Larsen E, Poulsen H, et al.
Diabetes Obes Metab
. 2020 Jun;
22(9):1639-1647.
PMID: 32543021
Aims: To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. Materials And...
4.
Johansen N, Dejgaard T, Lund A, Schluntz C, Frandsen C, Forman J, et al.
Lancet Diabetes Endocrinol
. 2020 Mar;
8(4):313-324.
PMID: 32135138
Background: In type 2 diabetes, long-acting GLP-1 receptor agonists lower fasting plasma glucose and improve glycaemic control via their insulinotropic and glucagonostatic effects. In type 1 diabetes, their efficacy as...
5.
Heimburger S, Bronden A, Johansen N, Dejgaard T, Vilsboll T, Knop F
Expert Opin Pharmacother
. 2019 Feb;
20(5):501-510.
PMID: 30730773
Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D)....